Eli Lilly and Company

J Scott Sawyer

Robert D Dillard

Michael J Sofia

S Richard Baker

Paul E Floreancig

This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.

Method of treating leukotriene caused diseases with N-benzyl

N-benzyl dihydroindole LTD.sub.4  antagonists

This invention provides certain 1,2,4,5 substituted benzene derivatives containing 'acid' substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

Leukotriene B4 antagonists

N-benzyl dihydroindole LTD.sub.4 antagonists

Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B.sub.4, one of the metabolites of arachidonic acid. The primary LTB.sub.4 antagonistic structures are represented as: ##STR1##

Substituted phenyl phenol leukotriene antagonists

Leukotriene B.sub.4 antagonists

Growing community of inventors

Indianapolis, IN, United States of America

J Scott Sawyer